Home > About > BRAF V600+ NSCLC > Clinical study
TAFINLAR + MEKINIST: An approved combination therapy for advanced NSCLC with a BRAF V600 mutation1,2
Efficacy and safety established in a Phase II, 3-cohort, multicenter, non-randomized, open-label study1,2
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) phase 2 study treatment-naïve and previously treated patient cohorts

- Primary End Point: Overall response rate (ORR) using RECIST 1.1 assessed by the investigator1-3
- Secondary End Points: Duration of response (DoR), progression-free survival (PFS), and overall survival (OS)1-3
Baseline patient characteristics in the phase II trial (cohorts B and C)
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) phase 2 study baseline characteristics


Occurrence of BRAF V600 mutation supports broad biomarker testing
